Fig. 3.

mTORC1 activity is impaired in ErbB2 + breast cancer cells lacking c-Src. a IF analysis of ErbB2 and phosphorylated forms of Rps6 and Eif4ebp1 in control and c-Src-deficient ErbB2 + mammary tumors. Scale bars represent 50 µm. b Left panel – immunoblots of Rps6 and Eif4ebp1 phosphorylation in control and c-Src-deficient ErbB2 + mammary tumors. Right panel - bar charts show quantification of phosphorylated Rps6 and Eif4ebp1 proteins (n = 7 tumors per genotype). c Left - representative immunoblots of PRC2 expression and mTORC1 signaling in NIC/c-Src^+/+ ErbB2 + breast cancer cells treated with the indicated inhibitors for 24 h (Ev: everolimus, 10 nM; Torin 1, 250 nM; Silv: silvestrol, 25 nM). Right - Quantification of Ezh2, Suz12 and Eed protein levels in four independent cell lines following the indicated treatments. All data in this figure are presented as mean ± SEM, where * = p < 0.05 and ** = p < 0.01; unpaired, two-tailed Student’s t-test